Komiyama S, Aoki D, Tominaga E, Susumu N, Udagawa Y, Nozawa S
School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Gynecol Oncol. 1999 Mar;72(3):342-6. doi: 10.1006/gyno.1998.5284.
Ovarian clear cell carcinoma is commonly associated with pelvic endometriosis. We retrospectively evaluated clinicopathological data on the association between ovarian clear cell carcinoma and pelvic endometriosis.
Between 1984 and 1995, we evaluated clinicopathological data on 53 Japanese patients with primary ovarian clear cell carcinoma who had been initially treated at Keio University Hospital. The clinical backgrounds and 5-year survival rates were evaluated.
Twenty (37.7%) of the 53 patients had carcinoma accompanied by pelvic endometriosis. These 20 cases were classified as FIGO stage I (n = 13, 65%), stage II (n = 1, 5%), stage III (n = 6, 30%), or stage IV (n = 0). The other 33 cases of ovarian clear cell carcinoma had no evidence of association with endometriosis and were classified as stage I (n = 19, 57.6%), stage II (n = 2, 6.1%), stage III (n = 9, 27.2%), or stage IV (n = 3, 9.1%). The incidence of a positive intraperitoneal cytology in stage Ic was significantly less in the group with endometriosis than in that without the endometriosis (n = 1, 14.3% vs n = 9, 64.3%, P = 0.03). The 5-year survival rate of stage I patients was significantly greater in ovarian clear cell carcinoma with pelvic endometriosis (100%) than in that without it (60%, P < 0.05).
Patients having ovarian clear cell carcinoma with pelvic endometriosis exhibited a better prognosis than those without endometriosis, especially those patients with stage I cancer.
卵巢透明细胞癌常与盆腔子宫内膜异位症相关。我们回顾性评估了卵巢透明细胞癌与盆腔子宫内膜异位症之间关联的临床病理数据。
1984年至1995年间,我们评估了53例在庆应义塾大学医院接受初始治疗的原发性卵巢透明细胞癌日本患者的临床病理数据。评估了临床背景和5年生存率。
53例患者中有20例(37.7%)的癌伴有盆腔子宫内膜异位症。这20例病例被分类为国际妇产科联盟(FIGO)分期I期(n = 13,65%)、II期(n = 1,5%)、III期(n = 6,30%)或IV期(n = 0)。其他33例卵巢透明细胞癌无子宫内膜异位症关联证据,被分类为I期(n = 19,57.6%)、II期(n = 2,6.1%)、III期(n = 9,27.2%)或IV期(n = 3,9.1%)。Ic期腹腔细胞学检查阳性的发生率在有子宫内膜异位症的组中显著低于无子宫内膜异位症的组(n = 1,14.3%对n = 9,64.3%,P = 0.03)。盆腔子宫内膜异位症的卵巢透明细胞癌I期患者的5年生存率(100%)显著高于无盆腔子宫内膜异位症的患者(60%,P < 0.05)。
患有盆腔子宫内膜异位症的卵巢透明细胞癌患者的预后比无子宫内膜异位症的患者更好,尤其是I期癌症患者。